{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:23:48Z","timestamp":1790421828076,"version":"4.1.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,9,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cytomegalovirus (CMV) infections remain a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), and standard antiviral therapies are associated with significant side effects and development of drug-resistant mutants. Adoptively transferred donor-derived CMV-specific T cells (CMVSTs) can provide an alternative treatment modality with few side effects but are not widely available due to their patient-specific nature. Here we report the establishment and use of a bank of CMVSTs derived from just 8 CMV-seropositive donors, with HLA types representing the diverse US population, as an \u201coff-the-shelf\u201d therapy to treat drug-refractory infections. To date, we have screened 29 patients for study participation and identified a suitable line, with \u22652 of 8 shared HLA antigens, for 28 (96.6%) patients with a median of 4 shared HLA antigens. Of these, 10 patients with persistent\/refractory CMV infections or disease were eligible for treatment; a single infusion of cells produced 3 partial responses and 7 complete responses, for a cumulative response rate of 100% (95% confidence interval, 69.2-100) with no graft-versus-host disease, graft failure, or cytokine release syndrome. Potential wider use of the tested CMVSTs across transplant centers is made more feasible by our ability to produce sufficient material to generate cells for &amp;gt;2000 infusions from a single donor collection. Our data indicate that a \u201cmini\u201d bank of CMVSTs prepared from just 8 well-chosen third-party donors can supply the majority of patients with an appropriately matched line that produces safe and effective anti-CMV activity post-HSCT.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000371","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T16:45:10Z","timestamp":1567529110000},"page":"2571-2580","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["\u201cMini\u201d bank of only 8 donors supplies CMV-directed T cells to diverse recipients"],"prefix":"10.1182","volume":"3","author":[{"given":"Ifigeneia","family":"Tzannou","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children\u2019s Hospital, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Watanabe","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children\u2019s Hospital, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Naik","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children\u2019s Hospital, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Daum","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children\u2019s Hospital, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manik","family":"Kuvalekar","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children\u2019s Hospital, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn S.","family":"Leung","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children\u2019s Hospital, Houston, TX;"},{"name":"Department of Pediatrics, Aflac Cancer and Blood Disorders Center of Children\u2019s Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caridad","family":"Martinez","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children\u2019s Hospital, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadir","family":"Sasa","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children\u2019s Hospital, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengfen","family":"Wu","sequence":"first","affiliation":[{"name":"Biostatistics Shared Resource\/Division of Biostatistics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian P.","family":"Gee","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children\u2019s Hospital, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Krance","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children\u2019s Hospital, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-7468","authenticated-orcid":false,"given":"Stephen","family":"Gottschalk","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children\u2019s Hospital, Houston, TX;"},{"name":"Department of Bone Marrow Transplant and Cellular Therapy, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen E.","family":"Heslop","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children\u2019s Hospital, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1479-5305","authenticated-orcid":false,"given":"Bilal","family":"Omer","sequence":"first","affiliation":[{"name":"Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital, Texas Children\u2019s Hospital, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"issue":"20","key":"2020021316133342000_B1","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood-2015-11-679639","article-title":"Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis","volume":"127","author":"Teira","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2020021316133342000_B2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.blre.2017.01.002","article-title":"The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: why the quest for meaningful prophylaxis still matters","volume":"31","author":"Chan","year":"2017","journal-title":"Blood Rev"},{"issue":"8","key":"2020021316133342000_B3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/21505594.2016.1221022","article-title":"CMV-specific immune reconstitution following allogeneic stem cell transplantation","volume":"7","author":"Blyth","year":"2016","journal-title":"Virulence"},{"issue":"3","key":"2020021316133342000_B4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/bmt.2009.172","article-title":"Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients","volume":"45","author":"Tormo","year":"2010","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"2020021316133342000_B5","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM199510193331603","article-title":"Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor","volume":"333","author":"Walter","year":"1995","journal-title":"N Engl J Med"},{"issue":"11","key":"2020021316133342000_B6","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2020021316133342000_B7","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nm1475","article-title":"Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals","volume":"12","author":"Leen","year":"2006","journal-title":"Nat Med"},{"issue":"6","key":"2020021316133342000_B8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","article-title":"Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Micklethwaite","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2020021316133342000_B9","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1086\/648422","article-title":"Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation","volume":"49","author":"Peggs","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"24","key":"2020021316133342000_B10","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1182\/blood-2009-04-214684","article-title":"The transfer of adaptive immunity to CMV during hematopoietic stem cell transplantation is dependent on the specificity and phenotype of CMV-specific T cells in the donor","volume":"114","author":"Scheinberg","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2020021316133342000_B11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/ciq042","article-title":"Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation","volume":"52","author":"Peggs","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"18","key":"2020021316133342000_B12","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2020021316133342000_B13","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"issue":"242","key":"2020021316133342000_B14","doi-asserted-by":"crossref","first-page":"242ra83","DOI":"10.1126\/scitranslmed.3008825","article-title":"Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT","volume":"6","author":"Papadopoulou","year":"2014","journal-title":"Sci Transl Med"},{"issue":"3","key":"2020021316133342000_B15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1537-2995.2010.02940.x","article-title":"Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation","volume":"51","author":"Schmitt","year":"2011","journal-title":"Transfusion"},{"issue":"12","key":"2020021316133342000_B16","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood-2014-06-573725","article-title":"Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT","volume":"125","author":"Feucht","year":"2015","journal-title":"Blood"},{"issue":"2","key":"2020021316133342000_B17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/sj.bmt.1705388","article-title":"Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially [published correction appears in Bone Marrow Transplant. 2006;38(5): 397]?","volume":"38","author":"Mehta","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2020021316133342000_B18","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2020021316133342000_B19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00262-009-0789-1","article-title":"A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation","volume":"59","author":"Uhlin","year":"2010","journal-title":"Cancer Immunol Immunother"},{"issue":"23","key":"2020021316133342000_B20","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","article-title":"Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes","volume":"116","author":"Barker","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2020021316133342000_B21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2141.2011.08579.x","article-title":"Third-party virus-specific T cells eradicate adenoviraemia but trigger bystander graft-versus-host disease","volume":"154","author":"Qasim","year":"2011","journal-title":"Br J Haematol"},{"issue":"8","key":"2020021316133342000_B22","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/cid\/cis625","article-title":"Rapid salvage treatment with virus-specific T cells for therapy-resistant disease","volume":"55","author":"Uhlin","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2020021316133342000_B23","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"issue":"26","key":"2020021316133342000_B24","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2020021316133342000_B25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.13051","article-title":"Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease","volume":"167","author":"Vickers","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"2020021316133342000_B26","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CJI.0000000000000031","article-title":"T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I\/II feasibility and safety study","volume":"37","author":"Gallot","year":"2014","journal-title":"J Immunother"},{"issue":"31","key":"2020021316133342000_B27","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"issue":"24","key":"2020021316133342000_B28","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv"},{"issue":"12","key":"2020021316133342000_B29","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group Report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020021316133342000_B30","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"2020021316133342000_bib31","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2146\/ajhp090424","article-title":"Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection","volume":"67","author":"Jacobsen","year":"2010","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"2020021316133342000_bib32","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1186\/s12879-017-2854-2","article-title":"Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients","volume":"17","author":"Robin","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"25","key":"2020021316133342000_bib33","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2020021316133342000_bib34","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/cid\/ciy696","article-title":"Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials","volume":"68","author":"Chemaly","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2020021316133342000_bib35","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am J Transplant"},{"issue":"9","key":"2020021316133342000_bib36","doi-asserted-by":"crossref","first-page":"e00922","DOI":"10.1128\/AAC.00922-18","article-title":"New locus of drug resistance in the human cytomegalovirus UL56 gene revealed by in vitro exposure to letermovir and ganciclovir","volume":"62","author":"Chou","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2020021316133342000_bib37","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"issue":"22","key":"2020021316133342000_bib38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.61.61","article-title":"Third party CMV-specific cytotoxic T cells for treatment of antiviral resistant CMV infection after hematopoietic stem cell transplant","volume":"128","author":"Prockop","year":"2016","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/17\/2571\/1716336\/advancesadv2019000371.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/17\/2571\/1716336\/advancesadv2019000371.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T16:13:58Z","timestamp":1581610438000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/17\/2571\/261380\/Mini-bank-of-only-8-donors-supplies-CMVdirected-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":38,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2019,9,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000371","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]}}}